Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
In the Literature

Bisphosphonates and skeletal morbidity in patients with metastatic cancer

Mohit Bhandari
CMAJ November 11, 2003 169 (10) 1053;
Mohit Bhandari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327: 469-72.

Background: Metastatic bone disease continues to represent a major challenge to physicians. Cancer patients with bone metastases can suffer from hypercalcemia, pathologic fractures, spinal cord compression, reduced mobility and pain. A completely satisfactory therapeutic option has yet to be found. Recent meta-analyses confirm the efficacy of bisphosphonates — potent medications that inhibit bone resorption — in increasing bone mineral density and reducing fracture rates.1 Whether these results with bisphosphonates can be extrapolated to patients with metastatic bone disease remains uncertain.

Question: In patients with proven malignant disease and bone metastases, does the use of oral or intravenous bisphosphonate therapy reduce skeletal morbidity (pathological fractures, radiotherapy to bone metastases, hypercalcemia, spinal cord compression and orthopedic surgery)?

Design: The investigators conducted a systematic review and meta-analysis of all available randomized trials evaluating the use of bisphosphonates in cancer patients with metastatic bone disease. Patients with multiple myeloma were included, but those with other hematological cancers were not. The investigators identified potentially relevant trials by searching electronic databases (MEDLINE, CancerLit, EMBASE, Science Citation Index, Cochrane Database), manually searching 3 oncology journals and abstracts from international meetings, scanning reference lists of articles, and consulting experts in the specialty and drug companies for unpublished data. All foreign-language articles were translated in full into English. The reporting of concealment and blinding in each trial was graded by the authors. Data were pooled when appropriate using a random effects model and weighted according to the inverse of their variance. No sensitivity analyses were defined a priori.

Results: Of 95 potentially relevant articles, 47 papers describing 30 studies met the eligibility criteria. Data extracted from 18 studies were eligible for inclusion in the meta-analyses. Patient populations included those with breast cancer, prostate cancer, multiple myeloma and mixed diagnoses. Compared with placebo, in the studies of more than 6 months' duration, bisphosphonates significantly reduced the odds ratio (OR) for vertebral fractures (7 studies [n = 3238], OR 0.69, 95% confidence interval [CI] 0.57–0.84), nonvertebral fractures (9 studies [n = 3376], OR 0.65, 95% CI 0.54–0.79), combined fractures (7 studies [n = 2587], OR 0.65, 95% CI 0.55–0.78), radiotherapy (8 studies [n = 3140], OR 0.67, 95% CI 0.57–0.79) and hypercalcemia (11 studies [n = 3894], OR 0.54, 95% CI 0.36–0.81). Bisphosphonates did not reduce the incidence of spinal cord compression (6 studies [n = 2628], OR 0.71, 95% CI 0.47–1.08). The risk of subsequent orthopedic surgery was reduced with bisphosphonates in the studies of more than 2 years' duration (2 studies [n = 753], OR 0.49, 95% CI 0.28–0.86).

Commentary: In the hierarchy of research design, the results of a meta-analysis of high-quality, homogeneous, randomized controlled trials represents the highest level of evidence to guide patient care.1,2,3 Ross and coauthors should be commended for their rigorous systematic review and meta-analysis. The validity of the results from this review are strengthened by the inclusion of randomized controlled trials, a comprehensive search strategy, the inclusion of unpublished reports and non-English-language trials, and homogeneity of results across studies.1,2,3 The authors did not report whether searches, assessment of study validity or data abstraction were performed in duplicate. The reproducibility of the methodology (i.e., inter-reviewer agreement statistics) would improve confidence in the validity of the review.

Practice implications: Bisphosphonates are effective in decreasing skeletal morbidity. Although morbidity is decreased and time to first skeletal event is increased, overall survival is not increased. Bisphosphonate therapy should be initiated when skeletal metastases are identified and continued for at least 6 months for clinical benefit. Although no direct comparison between intravenous and oral routes of administration were available, indirect comparisons favour the intravenous route.

Mohit Bhandari Department of Clinical Epidemiology and Biostatistics Division of Orthopaedic Surgery McMaster University Hamilton, Ont.

References

  1. 1.↵
    Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-16.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Guyatt GH, Rennie D, editors. User's guides to the medical literature: a manual for evidence-based clinical practice. Chicago: American Medical Association Press; 2002.
  3. 3.↵
    Montori VM, Swiontkowski MF, Cook DJ. Methodologic issues in systematic reviews and meta-analyses. Clin Orthop 2003;413:43-54.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (10)
CMAJ
Vol. 169, Issue 10
11 Nov 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bisphosphonates and skeletal morbidity in patients with metastatic cancer
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bisphosphonates and skeletal morbidity in patients with metastatic cancer
Mohit Bhandari
CMAJ Nov 2003, 169 (10) 1053;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Bisphosphonates and skeletal morbidity in patients with metastatic cancer
Mohit Bhandari
CMAJ Nov 2003, 169 (10) 1053;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Does the choice of β-blocker affect outcome in chronic heart failure?
  • ACE inhibition in stable coronary artery disease
Show more In the Literature

Similar Articles

Collections

  • Topics
    • Cancer & oncology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire